title: Gefitinib: a review of its use in adults with advanced non-small cell lung cancer.
abstract: Gefitinib (Iressa®) is a selective small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR TKI) indicated for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR tyrosine kinase. Large phase III or IV clinical trials in patients with locally advanced or metastatic NSCLC showed that gefitinib as first- or subsequent-line treatment significantly prolonged progression-free survival (PFS) and improved objective response rates and/or health-related quality of life parameters in patients with activating EGFR mutations and in clinically selected patients (e.g., Asian patients or never-smokers) who are more likely to harbour these mutations. Overall survival did not increase significantly with gefitinib, although post-study treatments may have had a confounding effect on this outcome. Gefitinib was generally well tolerated in these studies, with mild or moderate skin reactions, gastrointestinal disturbances and elevations in liver enzymes among the most common adverse reactions in gefitinib recipients; interstitial lung disease has also been reported in <6 % of gefitinib recipients. Compared with chemotherapy, gefitinib as first- or subsequent-line therapy provided similar or greater PFS benefit and was generally associated with fewer haematological adverse events, neurotoxicity, asthenic disorders, as well as grade ≥3 adverse events. Although the position of gefitinib with respect to other EGFR TKIs is not definitively established, current evidence indicates that gefitinib monotherapy is an effective and generally well-tolerated first- or subsequent-line treatment option for patients with NSCLC and activating EGFR mutations who have not received an EGFR TKI previously.
authors: Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand, demail@springer.com.
authors: Sohita
authors: S
authors: Dhillon
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D011799:Quinazolines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D000077156:Gefitinib
references: Ann Oncol. 2009 Sep;20(9):1483-8
references: 19282468
references: J Natl Cancer Inst. 2005 May 4;97(9):643-55
references: 15870435
references: Br J Cancer. 2014 Jan 7;110(1):55-62
references: 24263064
references: Clin Cancer Res. 2001 May;7(5):1459-65
references: 11350918
references: J Clin Oncol. 2008 Sep 10;26(26):4244-52
references: 18779611
references: Oncology. 2009;76(4):239-46
references: 19246948
references: BMC Cancer. 2011 Jan 01;11:1
references: 21194487
references: Int J Cancer. 2010 Feb 1;126(3):651-5
references: 19609951
references: J Clin Oncol. 2002 May 1;20(9):2240-50
references: 11980995
references: J Thorac Oncol. 2006 Oct;1(8):847-55
references: 17409969
references: J Thorac Oncol. 2011 Nov;6(11):1872-80
references: 22011650
references: N Engl J Med. 2010 Jun 24;362(25):2380-8
references: 20573926
references: J Clin Oncol. 2008 Dec 1;26(34):5589-95
references: 18794545
references: J Clin Oncol. 2006 Nov 1;24(31):5034-42
references: 17075123
references: J Clin Oncol. 2003 Jun 15;21(12):2237-46
references: 12748244
references: J Clin Oncol. 2004 Mar 15;22(6):1103-9
references: 15020612
references: Nat Clin Pract Oncol. 2006 Aug;3(8):448-57
references: 16894390
references: JAMA. 2003 Oct 22;290(16):2149-58
references: 14570950
references: Cancer. 2010 Jun 15;116(12):3025-33
references: 20564408
references: J Clin Oncol. 2011 Jul 20;29(21):2866-74
references: 21670455
references: Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5813-24
references: 14676101
references: Lung Cancer. 2013 Sep;81(3):328-36
references: 23809060
references: Lancet. 2008 Nov 22;372(9652):1809-18
references: 19027483
references: Oncotarget. 2010 Nov;1(7):497-514
references: 21165163
references: J Clin Oncol. 2002 Nov 1;20(21):4292-302
references: 12409327
references: Clin Cancer Res. 2010 Feb 15;16(4):1307-14
references: 20145166
references: Int J Med Sci. 2008 Jul 11;5(4):209-17
references: 18645621
references: J Clin Oncol. 2012 Apr 1;30(10):1122-8
references: 22370314
references: Lancet Oncol. 2012 Jan;13(1):e23-31
references: 21764376
references: J Clin Oncol. 2009 Mar 20;27(9):1394-400
references: 19224850
references: Respir Investig. 2014 Mar;52(2):82-91
references: 24636263
references: J Clin Oncol. 2013 Mar 10;31(8):1070-80
references: 23401451
references: J Clin Oncol. 2004 May 1;22(9):1589-97
references: 15117980
references: Drugs. 2009 Nov 12;69(16):2303-28
references: 19852530
references: PLoS One. 2014 Feb 12;9(2):e85245
references: 24533047
references: Lancet Oncol. 2012 May;13(5):528-38
references: 22452896
references: Ann Oncol. 2013 Jan;24(1):54-9
references: 22967997
references: N Engl J Med. 2005 Feb 24;352(8):786-92
references: 15728811
references: Ann Oncol. 2003 Jun;14(6):922-30
references: 12796031
references: Asia Pac J Clin Oncol. 2012 Sep;8(3):232-43
references: 22897752
references: Ann Oncol. 2012 Nov;23(11):2914-9
references: 22776705
references: Lung Cancer. 2012 Jan;75(1):82-8
references: 21684626
references: Am J Respir Crit Care Med. 2005 Sep 1;172(5):523-9
references: 15961694
references: Science. 2004 Jun 4;304(5676):1497-500
references: 15118125
references: Oncologist. 2012;17(6):863-70
references: 22581822
references: Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11
references: 15329413
references: Clin Lung Cancer. 2013 Mar;14(2):188-93
references: 22846582
references: Eur J Cancer. 2013 Jan;49(1):106-14
references: 22897841
references: N Engl J Med. 2004 May 20;350(21):2129-39
references: 15118073
references: Lung Cancer. 2014 Feb;83(2):174-81
references: 24361280
references: Lancet Oncol. 2010 Feb;11(2):121-8
references: 20022809
references: Jpn J Clin Oncol. 2013 Jun;43(6):664-8
references: 23585689
references: Onkologie. 2013;36(9):510-8
references: 24051929
references: Lung Cancer. 2013 Aug;81(2):280-7
references: 23540718
references: Science. 2007 May 18;316(5827):1039-43
references: 17463250
references: J Clin Oncol. 2005 Oct 1;23(28):6838-45
references: 15998906
references: J Natl Cancer Inst. 2005 Mar 2;97(5):339-46
references: 15741570
references: J Thorac Oncol. 2014 Sep;9(9):1345-53
references: 25122430
references: Cancer Discov. 2011 Sep;1(4):352-65
references: 22145099
references: Exp Ther Med. 2012 Feb;3(2):207-213
references: 22969870
references: J Clin Pathol. 2013 Feb;66(2):79-89
references: 23172555
references: Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37
references: 16257339
references: J Thorac Oncol. 2012 Jan;7(1):115-21
references: 21900837
references: Cancer Res. 2004 Dec 15;64(24):8919-23
references: 15604253
references: Lancet Oncol. 2013 Sep;14(10):953-61
references: 23948351
references: Ann Oncol. 2014 Sep;25(9):1681-90
references: 24718890
references: Cancer. 2012 Dec 15;118(24):6234-42
references: 22674612
references: Ann Oncol. 2014 Sep;25 Suppl 3:iii27-39
references: 25115305
references: Curr Med Chem. 2006;13(29):3483-92
references: 17168718
references: Anticancer Drugs. 2013 Nov;24(10):1039-46
references: 23962905
references: N Engl J Med. 2009 Sep 3;361(10):947-57
references: 19692680
references: Oncogene. 2008 Aug 7;27(34):4702-11
references: 18408761
references: J Clin Oncol. 2002 Jan 1;20(1):110-24
references: 11773160
references: Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2070-5
references: 18227510
references: Crit Rev Oncol Hematol. 2014 Feb;89(2):300-13
references: 24041630
references: Cancer Res. 2002 Oct 15;62(20):5749-54
references: 12384534
references: J Clin Oncol. 2010 Feb 10;28(5):744-52
references: 20038723
references: Target Oncol. 2013 Mar;8(1):27-33
references: 23361373
references: Am J Respir Crit Care Med. 2008 Jun 15;177(12):1348-57
references: 18337594
references: Clin Pharmacokinet. 2006;45(6):633-44
references: 16719544
references: J Clin Oncol. 2002 Sep 15;20(18):3815-25
references: 12228201
references: Ann Oncol. 2014 Aug;25(8):1475-84
references: 24669016
references: Expert Opin Ther Targets. 2012 Jan;16(1):15-31
references: 22239438